A multi-task graph deep learning model to predict drugs combination of synergy and sensitivity scores

Samar Monem1,2, Aboul Ella Hassanien3,4, Alaa H Abdel-Hamid5

  • 1Mathematics and Computer Science Department, Faculty of Science, Beni-Suef University, Beni Suef, 62521, Egypt. samarmahmoud@science.bsu.edu.eg.

BMC Bioinformatics
|October 10, 2024
PubMed
Abstract

Insights

This study introduces MultiComb, a deep learning model that predicts drug combination synergy and sensitivity for cancer treatment. The model shows improved performance over existing methods, aiding in the development of effective combination therapies.

Area of Science:

  • Computational biology
  • Pharmacology
  • Artificial intelligence

Background:

  • Drug combinations enhance efficacy and reduce side effects in treating complex diseases like cancer.
  • Multi-targeted drug combinations are crucial for maximizing therapeutic effects and achieving synergy.

Purpose of the Study:

  • To develop a multi-task deep learning (MTDL) model named 'MultiComb' for predicting drug combination synergy and sensitivity.
  • To simultaneously predict the synergistic and sensitivity scores of drug combinations against specific cancer cell lines.

Main Methods:

  • Utilized a graph convolution network to process drug SMILES (Simplified Molecular-Input Line-Entry) representations.
  • Employed fully connected subnetworks and an attention mechanism to extract and integrate drug and cancer cell line features.
  • Implemented a cross-stitch model to learn inter-task relationships for predicting synergy and sensitivity.

Main Results:

  • Validated on the O'Neil benchmark dataset (17,901 drug pairs across 37 cancer cell lines).
  • Achieved mean synergy scores of 232.37 (MSE), 9.59 (MAE), 0.57 (R²), 0.76 (Spearman), and 0.73 (Pearson).
  • Achieved mean sensitivity scores of 15.59 (MSE), 2.74 (MAE), 0.90 (R²), 0.95 (Spearman), and 0.95 (Pearson).

Conclusions:

  • The proposed MTDL model, MultiComb, effectively predicts drug combination synergy and sensitivity.
  • MultiComb demonstrates superior performance compared to existing methods for targeted cancer therapy development.

Related Concept Videos

Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
3.7K
Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
331
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
8.3K
Drug Concentration Versus Time Correlation01:15

Drug Concentration Versus Time Correlation

The plasma drug concentration-time curve is a crucial tool in pharmacokinetics, representing the drug's concentration in plasma at different time intervals post-administration. This curve illustrates the drug's journey from absorption into the systemic circulation, distribution to body tissues, and eventual elimination through excretion or biotransformation.
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
652
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
603
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.4K